(TheNewswire)
Calgary , Alberta – February 20,2024 – TheNewswire -- ForImmediate Release – nDatalyze Corp.(“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) ispleased to review its advanced mental conditiondiagnostic system that promises to fundamentallychange mental health diagnosis, management and treatment.
Introduction - nDatalyze Corp. ("NDAT") is at the forefront ofAI/ML-based (ML) mental health diagnostics through its YMI ClinicalDecision Support System. YMI is currently operational and undergoingvalidation by an elite team of researchers and clinical expertsthrough two Clinical Studies. Leveraging proprietary databases andalgorithms, YMI addresses the critical challenge of misdiagnosis inmental health.
James Durward, CEO, states: “Our purpose-built andproprietary databases are what really set us apart from others in thissector. While high quality ML algorithms are abundant, withoutrelevant, consistent, clean data to feed the ML algorithms, youcan’t get quality results. Perhaps an even bigger issue is copyright– while others must deal with potential copyright infringementclaims related to the training data they use, we have full rights toour data. We recognized the value of high quality data from the get-goand I believe that this is a major differentiator that positions NDATas a transformative player in the sector.”
Key Personnel andCollaborations - At the helm of nDatalyze Corp.is CEO Jim Durward, a visionary data scientist pivotal to thecompany's pioneering approach in mental health diagnostics. The teamis further strengthened by NDAT's President, Dr. Keith Courtney, PhD,Psychiatrist.
Significantly contributing to the clinical research are distinguishedacademics Dr. Andrew Greenshaw, PhD, Professor of Psychiatry andNeuroscience at the University of Alberta, and Dr. Bo Cao, PhD, CanadaResearch Chair in Computational Psychiatry. Their expertise isinstrumental in one Clinical Study, being conducted under the auspicesof the Canadian Mental Health Association (CMHA).
Another key collaboration involves Dr. Dale Stevens, Neuroscience PhD,from the Department of Psychology at York University. Dr. Stevens isleading a Clinical Study related to the incorporation of DNA data intothe predictive algorithm. The DNA-enhanced data collection wascompleted in January, 2024 and these records form part of NDAT’spurpose-built databases.
These collaborations underscore NDAT's commitment to ensuring itstechnologies meet the highest standards of efficacy and ethicalpractice, both critical factors for investor confidence.
Innovative Approach and MarketPositioning - NDAT’s collaborative approachdoes more than just advance the field of mental health; it positionsNDAT as a leader in a vast and growing market. By focusing oncombining predictive diagnostics, condition management and treatment,NDAT taps into an unmet need in the mental health sector, offering asolution that can potentially transform how mental conditions arediagnosed, managed and treated. This innovativestance not only underscores NDAT's technological prowess but alsohighlights its potential for significant market growth andimpact.
Regulatory Excellence andPatient Safety - In its unwavering pursuit ofexcellence, nDatalyze Corp. (NDAT) places a strong emphasis onregulatory compliance and ethical standards. NDAT conducts extensiveethics reviews in collaboration with its academic partners, ensuringfull adherence to applicable regulations. This strict compliance notonly demonstrates NDAT's commitment to patient safety but alsounderlines its dedication to sustainable growth in the mental healthsector. By prioritizing these aspects, NDAT aligns itself with thehighest standards of practice, reinforcing investor confidence in thecompany's operational integrity and long-term viability. This approachis particularly crucial in the healthcare industry, where regulatorycompliance and patient safety are paramount.
Capital - NDAThas sufficient funds on hand to fund both Clinical Studies. NDAT hasno debt.
Engagement Invitation to Investors - nDatalyze Corp. cordially invites the investmentcommunity to explore the unique and innovative approach we haveadopted towards mental health care. We are eager to engage in furtherdiscussions about our strategic direction and the exciting investmentopportunities that lie ahead.
Dr. Keith Courtney, President (psychiatricaspects)
Email: drkeithcourtney@gmail.com
or
James Durward, CEO&CTO (technical aspects)
Tel: (403) 689-3901
Email: jimd@ndatalyze.com
nDatalyze Website: https://www.ndatalyze.com
About YMI: YMIuses evidence-based, objective data from whole life experiences topredict individual mental states over time, and applies this knowledgetowards a fuller understanding of how mental health develops, and howto improve mental wellbeing. YMI combines supervised machine-learningwith a proprietary Reference Database to predict an individual’spredisposition toward a variety of common mental conditions, bothcurrent and forward in time. YMI is poised to revolutionize mentalhealth diagnoses while ensuring a sustainable revenue stream. Bystrategically addressing the causes of misdiagnosis, establishingcredibility through clinical studies, and targeting key markets, YMIaligns both societal impact and financial success.
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in the policiesof the Canadian Securities Exchange) accepts responsibility for theadequacy or accuracy of this release. This news release does notconstitute an offer to sell or a solicitation of an offer to sell anyof the securities in the United States. The securities have not beenand will not be registered under the United States Securities Act of1933, as amended (the "U.S. Securities Act") or any statesecurities laws and may not be offered or sold within the UnitedStates or to U.S. Persons unless registered under the U.S. SecuritiesAct and applicable state securities laws or an exemption from suchregistration is available. The information in this news releaseincludes certain information and statements about management's view offuture events, expectations, plans and prospects that constituteforward looking statements. These statements are based uponassumptions that are subject to significant risks and uncertainties.Because of these risks and uncertainties and as a result of a varietyof factors, the actual results, expectations, achievements orperformance may differ materially from those anticipated and indicatedby these forward-looking statements. Any numberof factors could cause actual results to differ materially from theseforward-looking statements as well as future results. Although theCorporation believes that the expectations reflected in forwardlooking statements are reasonable, it can give no assurances that theexpectations of any forward-looking statements will prove to becorrect. Except as required by law, the Corporation disclaims anyintention and assumes no obligation to update or revise anyforward-looking statements to reflect actual results, whether as aresult of new information, future events, changes in assumptions,changes in factors affecting such forward-looking statements orotherwise.
Copyright (c) 2024 TheNewswire - All rights reserved.